ライフサイエンスコーパス: gastric bypass

1 s standard Roux-en-Y gastric bypass surgery (gastric bypass).

2 ns in short-term outcomes after laparoscopic gastric bypass.

3 loose stools were more frequent after distal gastric bypass.

4 pital admissions compared with patients with gastric bypass.

5 greater after duodenal switch compared with gastric bypass.

6 reduced after duodenal switch compared with gastric bypass.

7 y developed for bariatric patients requiring gastric bypass.

8 mbination of both methods, such as Roux-en-Y gastric bypass.

9 1 activity contributes to hypoglycemia after gastric bypass.

10 heir association with 30-day mortality after gastric bypass.

11 d as primary goal the changes in HDL-C after gastric bypass.

12 hyperinsulinemic hypoglycemia syndrome after gastric bypass.

13 himself or herself performing a laparoscopic gastric bypass.

14 e gastric banding and laparoscopic Roux-en-Y gastric bypass.

15 hanges seen in weight loss without Roux-en-Y gastric bypass.

16 were randomly assigned to undergo Roux-en-Y gastric bypass.

17 was reduced by 50% in the obese group after gastric bypass.

18 al-jejunal bypass component of the Roux-en-Y gastric bypass.

19 pertension, and dyslipidemia after Roux-en-Y gastric bypass.

20 t and of adult controls undergoing Roux-en-Y gastric bypass.

21 ustable gastric banding to 76% for Roux-en-Y gastric bypass.

22 ation of the common channel following distal gastric bypass.

23 and hemoglobin A1c were greater after distal gastric bypass.

24 l comorbidities at 1 year after laparoscopic gastric bypass.

25 or older, and 8681 (98.5%) were treated with gastric bypass.

26 ion, 0.089 in colorectal resection, 0.085 in gastric bypass, 0.072 in cholecystectomy, and 0.060 in i

27 ection (7.1% of hospitals), and laparoscopic gastric bypass (11.5% of hospitals) were the only proced

28 19%), vertical banded gastroplasty (69%), or gastric bypass (12%); nonrandomized, matched, prospectiv

29 Bariatric procedures, which included 74% gastric bypass, 15% sleeve gastrectomy, 10% adjustable g

30 Patients undergoing Roux-en-Y gastric bypass (161 participants) or sleeve gastrectomy

31 d with a greater BMI reduction than standard gastric bypass 2 years after surgery.

32 Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29

33 luded laparoscopic gastric banding (n=1053), gastric bypass (795), and sleeve gastrectomy (317), with

34 cedure for mouse and rat models of Roux-en-Y gastric bypass (80-90 min operative time) and sleeve gas

35 -GB), 7 patients who were asymptomatic after gastric bypass (A-GB), and 8 healthy control subjects un

36 rated the overall effectiveness of Roux-en-Y gastric bypass, adjustable gastric banding, and most rec

37 The greatest effect size was observed for gastric bypass (adjusted RR, 43.1; 95% CI, 19.7-94.5), f

38 Interventions: Standard gastric bypass (alimentary limb, 150 cm) and distal gast

39 more adverse outcomes than those undergoing gastric bypass alone.

40 Eight (42%) patients who underwent gastric bypass and 13 (68%) patients who underwent bilio

41 was 17.8 (95% CI, 16.9-18.6) after standard gastric bypass and 17.2 (95% CI, 16.3-18.0) after distal

42 78% women): 1513 who had undergone Roux-en-Y gastric bypass and 509 who had undergone laparoscopic ad

43 Roux-en-Y gastric bypass and biliopancreatic diversion can markedl

44 1.0-16.1) and 22.1 (95% CI, 19.5-24.7) after gastric bypass and duodenal switch, respectively.

45 verse outcome rates were similar for primary gastric bypass and for procedures following failed adjus

46 is in patients undergoing bariatric surgery (gastric bypass and gastric banding).

47 0.12-0.71) and 0.53 (95% CI, 0.08-3.56) for gastric bypass and gastric banding, respectively.

48 0.33-0.81) and 1.23 (95% CI, 0.40-3.75) for gastric bypass and gastric banding, respectively.

49 0.23-0.86) and 1.18 (95% CI, 0.12-11.49) for gastric bypass and gastric banding, respectively.

50 identified 12364 and 1071 patients receiving gastric bypass and gastric banding, respectively.

51 Laparoscopic gastric bypass and laparoscopic duodenal switch.

52 omparison between 30-day outcomes of primary gastric bypass and procedures following failed adjustabl

53 Gastric bypass and sleeve gastrectomy have a greater eff

54 HDL-C and ApoA4 significantly increase after gastric bypass and that this increase is associated with

55 ts who have undergone laparoscopic Roux-en-Y gastric bypass and to develop decision tree models to op

56 Bariatric surgeries, such as Roux-en-Y gastric bypass and vertical sleeve gastrectomy, produce

57 ng of the microbiome changes after Roux-en-Y gastric bypass and weight loss; and (3) a basis for unde

58 years, changes from baseline observed in the gastric-bypass and sleeve-gastrectomy groups were superi

59 tric Surgery (85 women underwent a Roux-en-Y gastric bypass, and 21 women underwent laparoscopic adju

60 er after distal gastric bypass than standard gastric bypass, and between-group differences were 19 mg

61 , 25 to 30) among participants who underwent gastric bypass, and by 26% (95% CI, 22 to 30) among thos

62 ss and 17.2 (95% CI, 16.3-18.0) after distal gastric bypass, and the mean between-group difference wa

63 rs) with severe obesity undergoing Roux-en-Y gastric bypass at three specialised paediatric obesity t

64 e reduced after VSG, but not after Roux-en-Y gastric bypass, based on enzyme-linked immunosorbent ass

65 ndergoing primary or revisional laparoscopic gastric bypass between January 1, 2004, and June 30, 201

66 Hypoglycemia after gastric bypass can be corrected by administration of a G

67 c banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce remarkable health improvemen

68 Roux-en-Y gastric bypass causes increased secretion of glucagon-li

69 n BMI, 6.4 +/- 0.7) than those who underwent gastric bypass (change in BMI, 14.0 +/- 0.5) (P < .0001)

70 atric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass), colorectal surgery (colectomy, proctect

71 bypass (alimentary limb, 150 cm) and distal gastric bypass (common channel, 150 cm), both with a bil

72 cantly greater in subjects who had undergone gastric bypass compared to the controls and in the H-GB

73 and 22 of 48 (45.8%) patients randomized to gastric bypass, considering office and 24-hour ambulator

74 fined, most micronutrient deficiencies after gastric bypass currently can be prevented or treated by

75 ely 11 % of patients who underwent Roux-en-Y gastric bypass develop symptomatic gallstone disease.

76 2013 with the terms "bariatric filter" and "gastric bypass filter." Two investigators independently

77 people aged 13-21 years underwent Roux-en-Y gastric bypass for clinically severe obesity at a paedia

78 investigate whether the benefits and risk of gastric bypass for type 2 diabetes can be balanced.

79 Data on 22,327 patients undergoing primary gastric bypass from January 1, 2008, to June 30, 2012, w

80 were included if they described outcomes for gastric bypass, gastric band, or sleeve gastrectomy perf

81 ors for developing marginal ulcer (MU) after gastric bypass (GBP) surgery for obesity.

82 Gastric bypass (GBP) surgery, one of the most common bar

83 In all years, laparoscopic Roux-en-Y gastric bypass generated the highest number of wRVUs (wR

84 ssure occurred in 41 of 49 patients from the gastric bypass group (83.7%) compared with 6 of 47 patie

85 ore nutritional deficiencies occurred in the gastric bypass group (mainly deficiencies in iron, album

86 Significantly more participants in the gastric bypass group achieved the composite triple endpo

87 8 participants (49%; 95% CI, 36%-63%) in the gastric bypass group and 11 (19%; 95% CI, 10%-32%) in th

88 surgical patients (seven [37%] of 19 in the gastric bypass group and 12 [63%] of 19 in the bilipancr

89 lly important adverse events occurred in the gastric bypass group and 25 in the lifestyle and medical

90 p compared with only one complication in the gastric bypass group and no complications in the biliopa

91 Eleven patients (22.4%) from the gastric bypass group and none in the control group were

92 atients who achieved 2 year remission in the gastric bypass group and seven (37%) of the 19 patients

93 The gastric bypass group experienced more nutritional defici

94 Across both years of the study, the gastric bypass group had seven serious falls with five f

95 Participants in the gastric bypass group required 3.0 fewer medications (mea

96 el adjusted for site, the event rate for the gastric bypass group was non-significantly higher than t

97 There were 22 serious adverse events in the gastric bypass group, including 1 cardiovascular event,

98 e and medical management group, eight in the gastric bypass group]).

99 group, as compared with 38% of those in the gastric-bypass group (P<0.001) and 24% of those in the s

100 group versus 42% (21 of 50 patients) in the gastric-bypass group (P=0.002) and 37% (18 of 49 patient

101 eline, with reductions of 24.5+/-9.1% in the gastric-bypass group and 21.1+/-8.9% in the sleeve-gastr

102 Weight loss was greater in the gastric-bypass group and sleeve-gastrectomy group (-29.4

103 e patients with recurrent hypoglycemia after gastric bypass (H-GB), 7 patients who were asymptomatic

104 nts with severe obesity undergoing Roux-en-Y gastric bypass had substantial weight loss over 5 years,

105 Gastric bypass has better outcomes than gastric band pro

106 ar percent weight change following Roux-en-Y gastric bypass, ie, weekly self-weighing, continuing to

107 e long-term (>5 years) outcomes of Roux-en-Y gastric bypass in a cohort of young adults who had under

108 dictor of diabetes remission after Roux-en-Y gastric bypass in obesity.

109 safety of standard gastric bypass vs distal gastric bypass in patients with a BMI of 50 to 60.

110 y, 2007, 74 young people underwent Roux-en-Y gastric bypass in the FABS study.

111 olescents and of adults undergoing Roux-en-Y gastric bypass, in the Adolescent Morbid Obesity Surgery

112 Complications after Roux-en-Y gastric bypass include anastomotic leaks and strictures,

113 ly relevant micronutrient deficiencies after gastric bypass include thiamine, vitamin B(1)(2), vitami

114 Roux-en-Y gastric bypass induced significantly greater weight loss

115 icrobial sequencing analyses after Roux-en-Y gastric bypass is the comparative overabundance of Prote

116 A Roux-en-Y gastric bypass is the procedure of choice when GERD and

117 Bariatric surgery, and in particular, gastric bypass, is an increasingly utilized and successf

118 res performed include laparoscopic Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding,

119 pic Roux-en-Y gastric bypass, open Roux-en-Y gastric bypass, laparoscopic gastric band placement, or

120 ngitudinal Database) for 51,788 laparoscopic gastric bypass (LRYGB) procedures performed between 2007

121 h of stay (LOS) after laparoscopic Roux-en-Y gastric bypass (LRYGB) should be 1 day to improve resour

122 st as often in Europe as laparoscopic Roux-Y-Gastric Bypass (LRYGB).

123 t standard procedure, laparoscopic Roux-en-Y gastric bypass (LRYGB).

124 Following standard gastric bypass, many of these patients still have a BMI

125 to the study, of whom 81 underwent Roux-en-Y gastric bypass (mean age 16.5 years [SD 1.2], bodyweight

126 Factors significantly associated with 30-day gastric bypass mortality included increasing body mass i

127 medication), remission rates were 38.2% for gastric bypass ( n = 808) and 17.4% for gastric band (n

128 Roux-en-Y gastric bypass (n = 161), sleeve gastrectomy (n = 67), o

129 were randomly assigned and operated on with gastric bypass (n = 31) and duodenal switch (n = 29).

130 size-weighted remission rates were 66.7% for gastric bypass (n = 428) and 28.6% for gastric band (n =

131 <200 mg/dL), remission rates were 60.4% for gastric bypass (n = 477) and 22.7% for gastric band (n =

132 , vertical banded gastroplasty (n = 227), or gastric bypass (n = 55) procedures were performed in the

133 ither medical treatment (n=20) or surgery by gastric bypass (n=20) or biliopancreatic diversion (n=20

134 agement alone (n=60) or with the addition of gastric bypass (n=60).

135 years (range: 5-9) after surgery (Roux-en-Y gastric bypass, n = 162; gastric banding, n = 32; sleeve

136 ity and who underwent laparoscopic Roux-en-Y gastric bypass, open Roux-en-Y gastric bypass, laparosco

137 173 patients undergoing primary laparoscopic gastric bypass operation for morbid obesity between May

138 Adults having had a laparoscopic Roux-en-Y gastric bypass or a laparoscopic vertical sleeve gastrec

139 f alcohol abuse among patients who underwent gastric bypass or a restrictive procedure (incidence rat

140 er medical treatment or surgery by Roux-en-Y gastric bypass or biliopancreatic diversion.

141 nventional medical therapy or undergo either gastric bypass or biliopancreatic diversion.

142 All Danish citizens who received gastric bypass or gastric banding between January 1, 199

143 tive patients scheduled to undergo Roux-en-Y gastric bypass or sleeve gastrectomy in three bariatric

144 efits, bariatric surgery and, in particular, gastric bypass or sleeve gastrectomy may be considered a

145 on to a different bariatric procedure (eg, a gastric bypass or sleeve gastrectomy).

146 or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

147 or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

148 ymptomatic gallstone disease after Roux-en-Y gastric bypass or sleeve gastrectomy.

149 ypass (OR 6.48, CI 2.17-19.41); laparoscopic gastric bypass (OR 3.97, CI 1.77-8.91); and sleeve gastr

150 odenal switch (OR 9.45, CI 2.50-35.97); open gastric bypass (OR 6.48, CI 2.17-19.41); laparoscopic ga

151 Patients who had a sleeve gastrectomy, gastric bypass, or duodenal switch were more likely to a

152 persistent NASH (30.4% vs 7.6% of those with gastric bypass; P = .015).

153 Patients were randomized to Roux-en-Y gastric bypass plus medical therapy or medical therapy a

154 ing strong evidence that patients undergoing gastric bypass procedure after failed gastric banding ha

155 analysis, 63,171 (95.3%) underwent a primary gastric bypass procedure and 3132 patients (4.7%) underw

156 Patients undergoing a gastric bypass procedure concomitant with a band-related

157 ry gastric bypass surgery with those who had gastric bypass procedures performed as a rescue procedur

158 Roux-en-Y Gastric Bypass remains an excellent and durable operatio

159 In this nationwide study, gastric bypass resulted in large improvements in obesity

160 Roux-en-Y gastric bypass reversed all of these DIO-induced effects

161 Laparoscopic Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastri

162 Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) accoun

163 id glycemic improvements following Roux-en-Y gastric bypass (RYGB) are frequently attributed to the e

164 pment and ultimate remission after Roux-en-Y gastric bypass (RYGB) are not fully understood.

165 The antidiabetes effects of Roux-en-Y gastric bypass (RYGB) are well-known, but the underlying

166 veness and long-term durability of Roux-en-Y Gastric Bypass (RYGB) at an accredited center.

167 esolution of type 2 diabetes after Roux-en-Y gastric bypass (RYGB) attests to the important role of t

168 l cohort of veterans who underwent Roux-en-Y gastric bypass (RYGB) compared with nonsurgical matches

169 provement in type 2 diabetes after Roux-en-Y gastric bypass (RYGB) has been attributed partly to weig

170 isional laparoscopic surgery after Roux-en-Y gastric bypass (RYGB) has been linked to substantial com

171 tprandial glucose metabolism after Roux-en-Y gastric bypass (RYGB) has been the subject of uncertaint

172 Roux-en-Y gastric bypass (RYGB) improves glucose homeostasis indep

173 Roux-en-Y gastric bypass (RYGB) improves glycemic control within d

174 e to the early and late effects of Roux-en-Y gastric bypass (RYGB) in 22 patients with T2D and 16 wit

175 Roux-en-Y gastric bypass (RYGB) involves exclusion of major parts

176 regain or insufficient loss after Roux-en-Y gastric bypass (RYGB) is common.

177 OUND AND AIMS: Hyperoxaluria after Roux-en-Y gastric bypass (RYGB) is generally attributed to fat mal

178 Roux-en-Y gastric bypass (RYGB) is highly effective in reversing o

179 The effect of a Roux-en-Y gastric bypass (RYGB) on body weight has been amply docu

180 further evidence for the impact of Roux-en-Y gastric bypass (RYGB) on both glycemic control and DPN i

181 of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) on liver function in bariatric pat

182 nt Procedural Terminology code for Roux-en-Y gastric bypass (RYGB) or adjustable gastric banding (AGB

183 in and physical function following Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric

184 Three years after Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric

185 abetes mellitus were randomized to Roux-en-Y gastric bypass (RYGB) or to hypocaloric diet (HC diet) r

186 Bariatric procedures, such as Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VS

187 Roux-en-Y gastric bypass (RYGB) produces substantial body weight (

188 Roux-en-Y gastric bypass (RYGB) reduces body weight and cardiovasc

189 drug use among patients undergoing Roux-en-Y gastric bypass (RYGB) surgery and a matched population-b

190 Both Roux-en-Y gastric bypass (RYGB) surgery and exercise can improve i

191 Existing mouse models of Roux-en-Y gastric bypass (RYGB) surgery are not comparable to huma

192 ms of metabolic improvements after Roux-en-Y gastric bypass (RYGB) surgery are not entirely clear.

193 n the prevalence of symptoms after Roux-en-Y gastric bypass (RYGB) surgery are sparse.

194 Roux-en-Y gastric bypass (RYGB) surgery causes profound weight los

195 ount of weight loss attained after Roux-en-Y gastric bypass (RYGB) surgery follows a wide and normal

196 ease and weight loss 5 years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a la

197 e 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery for patients taking insuli

198 namic (PD) study to assess whether Roux-en-Y gastric bypass (RYGB) surgery is associated with signifi

199 Roux-en-Y gastric bypass (RYGB) surgery is one of the most efficie

200 pe 2 diabetes mellitus who undergo Roux-en-Y gastric bypass (RYGB) surgery or standard medical care r

201 Roux-en-Y gastric bypass (RYGB) surgery results in exaggerated pos

202 CAAs) after weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery than after calorie restric

203 d metabolism are upregulated after Roux-en-Y gastric bypass (RYGB) surgery, which contributes to a we

204 rs can be improved or prevented by Roux-en-Y gastric bypass (RYGB) surgery.

205 iation with weight loss induced by Roux-in-Y gastric bypass (RYGB) surgery.

206 ctors associated with mortality in Roux-en-Y gastric bypass (RYGB) surgery.

207 d following weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery.

208 to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery.

209 e., a sleeve gastrectomy, proximal Roux-en Y gastric bypass (RYGB), and distal RYGB].

210 Roux-en-Y gastric bypass (RYGB), laparoscopic adjustable gastric b

211 e markers for T2DM remission after Roux-en-Y gastric bypass (RYGB).

212 poprotein A-IV (apoA-IV) rise with Roux-en-Y gastric bypass (RYGB).

213 emia (PHH) is often reported after Roux-en-Y gastric bypass (RYGB).

214 rs and long-term weight loss after Roux-en-Y gastric bypass (RYGB).

215 or 2 years or surgical treatments (Roux-en-Y gastric bypass [RYGB] or laparoscopic adjustable gastric

216 Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG) have

217 remission of type 2 diabetes after Roux-en-Y gastric bypass (RYGBP) are still puzzling.

218 cts of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGBP) on heme- and nonheme-iron absorpt

219 Long-term health maintenance after Roux-en-Y gastric bypass should focus on adherence to dietary supp

220 e for bariatric surgery, including Roux-en-Y gastric bypass, sleeve gastrectomy, or adjustable gastri

221 type of surgery (gastric banding, Roux-en-Y gastric bypass, sleeve gastrectomy, or other/unknown).

222 t to body weight (-23%, -19%, and -5% in the gastric-bypass, sleeve-gastrectomy, and medical-therapy

223 All gastric bypass studies (6 prospective cohorts, 5 retrosp

224 The gastric bypass subset was composed of 9480 (76.7%) women

225 tical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass surgeries for obesity.

226 secretion of gut hormones following certain gastric bypass surgeries.

227 d medical management plus standard Roux-en-Y gastric bypass surgery (gastric bypass).

228 Gastric bypass surgery (GBP) promotes early improvements

229 on for depression and death by suicide after gastric bypass surgery (GBP).

230 demonstrate that patients who have undergone gastric bypass surgery (GBS) have a higher risk of inpat

231 pants received either laparoscopic Roux-en-Y gastric bypass surgery (n = 100) or laparoscopic adjusta

232 2 diabetes mellitus shortly after Roux-en-Y gastric bypass surgery (RYGB) and before there is major

233 Roux-en-Y gastric bypass surgery (RYGB) results in remission of in

234 ve treatment for morbid obesity is Roux-en-Y gastric bypass surgery (RYGB), which results in rapid re

235 Roux-en-Y gastric bypass surgery (RYGBP), the most commonly perfor

236 A cohort of 7925 patients undergoing gastric bypass surgery and 7925 group-matched, severely

237 e 2 diabetes mellitus-1 managed by Roux-en-Y gastric bypass surgery and a comparable group managed me

238 ack of mortality benefit in those undergoing gastric bypass surgery at ages younger than 35 years pri

239 nts with type 2 diabetes mellitus undergoing gastric bypass surgery between January 2000 and July 200

240 Gastric bypass surgery can dramatically improve type 2 d

241 Patients undergoing gastric bypass surgery had a significantly lower age-rel

242 with the control group, the group undergoing gastric bypass surgery had a significantly reduced incid

243 The group undergoing gastric bypass surgery had greater percentage of excess

244 benefits and harms of laparoscopic Roux-en-Y gastric bypass surgery in patients defined by weight cla

245 Although gastric bypass surgery induces rapid weight loss and ame

246 Gastric bypass surgery is protective against mortality e

247 We hypothesized that gastric bypass surgery leads to a lower incidence of hea

248 Gastric bypass surgery leads to marked improvements in g

249 patients who undergo laparoscopic Roux-en-Y gastric bypass surgery may be at increased risk for alco

250 l in Boston, Massachusetts, and involved 770 gastric bypass surgery patients between January 1, 2007,

251 The 25 804 gastric bypass surgery patients had on average lost 18.8

252 cipants who underwent laparoscopic Roux-en-Y gastric bypass surgery reported a significant increase i

253 INTERPRETATION: Roux-en-Y gastric bypass surgery resulted in substantial and durab

254 Patients undergoing gastric bypass surgery seen at a private surgical practi

255 obese patients with type 2 diabetes, adding gastric bypass surgery to lifestyle and medical manageme

256 Potential benefits of adding gastric bypass surgery to the best lifestyle and medical

257 between those undergoing and not undergoing gastric bypass surgery using HRs.

258 Gastric bypass surgery was associated with approximately

259 Gastric bypass surgery was associated with improved long

260 surgery, adjusted all-cause mortality after gastric bypass surgery was significantly lower for patie

261 erm outcomes for patients undergoing primary gastric bypass surgery with those who had gastric bypass

262 a hospital cohort of individuals undergoing gastric bypass surgery, and DMGV levels fell in parallel

263 milar levels of endogenous GLP-1 occur after gastric bypass surgery, and mechanistic studies indicate

264 that after 10 years of follow-up, Roux-en-Y gastric bypass surgery, compared with nonsurgical medica

265 There is increasing evidence that after gastric bypass surgery, patients and animal models show

266 with diabetes remission following Roux-en-Y gastric bypass surgery, suggesting new therapeutic appro

267 of DMV neurones were not reversed following gastric bypass surgery, suggesting that they may be due

268 Among the 7925 patients who underwent gastric bypass surgery, the mean (SD) age at surgery was

269 For laparoscopic gastric bypass surgery, we used empirical Bayes techniqu

270 o inflammatory status, and was restored upon gastric bypass surgery-induced weight loss in morbid obe

271 5.6) years) weight loss following Roux-en-Y gastric bypass surgery.

272 ontributing to the control of diabetes after gastric bypass surgery.

273 for serious complications after laparoscopic gastric bypass surgery.

274 h glycemic deterioration and decreased after gastric bypass surgery.

275 edical management intervention and Roux-en-Y gastric bypass surgery.

276 the response of bariatric patients following gastric bypass surgery.

277 tprandial glycemia excursions increase after gastric bypass surgery; this effect is even greater amon

278 x, 41.8 +/- 6.3 kg/m(2); 46 +/- 11 y) during gastric-bypass surgery.

279 patients who sought and underwent Roux-en-Y gastric bypass (surgery group), 417 patients who sought

280 were higher among patients who had undergone gastric bypass than controls and increased with administ

281 year Framingham risk score were lower in the gastric bypass than in the control group.

282 serious complication rates with laparoscopic gastric bypass than other measures.

283 rotein cholesterol were greater after distal gastric bypass than standard gastric bypass, and between

284 bservational, prospective study of Roux-en-Y gastric bypass that was conducted in the United States.

285 eatment risks 2 years after adding Roux-en-Y gastric bypass to intensive lifestyle and medical manage

286 The addition of gastric bypass to lifestyle and medical management in pa

287 d with 14 of 49 patients (29%) who underwent gastric bypass (unadjusted P=0.01, adjusted P=0.03, P=0.

288 esection, pancreatic resection, laparoscopic gastric bypass, ventral hernia repair, abdominal aortic

289 Laparoscopic Roux-en-Y gastric bypass, vertical sleeve gastrectomy, and adjusta

290 o assess the efficacy and safety of standard gastric bypass vs distal gastric bypass in patients with

291 -up for LAGB was 54.2% EWL and for Roux-en-Y gastric bypass was 54.0% EWL.

292 eighted percentage of excess weight loss for gastric bypass was 65.7% (n = 3544) vs 45.0% (n = 4109)

293 Gastric bypass was associated with a significantly reduc

294 However, gastric bypass was associated with additional surgical i

295 Laparoscopic Roux-en-Y gastric bypass was consistently among the top 10 procedu

296 Conclusions and Relevance: Distal gastric bypass was not associated with a greater BMI red

297 A Roux-en-Y gastric bypass was performed in morbidly obese patients.

298 e levels 5 years after surgery compared with gastric bypass while improvements in health-related qual

299 nts who had undergone laparoscopic Roux-en-Y gastric bypass with surgically confirmed IH (n = 76) and

300 adolescent surgical patients after Roux-en-Y gastric bypass with those of conservatively treated adol